REGENXBIO Inc.
8-K February 10, 2026
Key Highlights
- REGENXBIO is a biotechnology company focused on gene therapies.
- RGX-121 is a potential first-in-class gene therapy for Mucopolysaccharidosis typ...
- Data from Phase 1/2 and Phase 2/3 clinical trials for RGX-121 showed promising r...
Read Analysis
🤖 AI Generated